Top > Search of International Patents > MUCOSAL VACCINE COMPOSITION FOR BOVINE MASTITIS

MUCOSAL VACCINE COMPOSITION FOR BOVINE MASTITIS

Foreign code F200010058
File No. 6099
Posted date May 15, 2020
Country WIPO
International application number 2019JP030451
International publication number WO 2020027318
Date of international filing Aug 2, 2019
Date of international publication Feb 6, 2020
Priority data
  • P2018-147175 (Aug 3, 2018) JP
Title MUCOSAL VACCINE COMPOSITION FOR BOVINE MASTITIS
Abstract A mucosal vaccine composition for preventing bovine mastitis, which comprises: an antigen originated from Staphylococcus aureus; and a nano gel comprising a polysaccharide having a cationic functional group and a hydrophobic functional group in side chains thereof. When the composition is administered to a cow, the titer of an antibody against Staphylococcus aureus increases immediately after the contact with the bacterium in the breast of the cow. Therefore, the composition can prevent the occurrence of mastitis in the cow.
Outline of related art and contending technology BACKGROUND ART
Mastitis is, bacteria from the mouth entering the nipple of the breast and the mammary gland, mammary gland by repeating the growth and fixing, mammary gland cells from being damaged in inflammation, infectious disease.
Mastitis is dairy, milk production throughout the world including Japan occurs in the field, the higher its occurrence frequency. Suffering from breast milk cow is, quality and amount is lowered. In addition, treatment with antibiotics for mastitis usually are performed, during the treatment period of milk remaining in the antibiotic, cannot be shipped. Moreover, is treated with antibiotics do is when, not economically viable for cattle handling and waste, disposal may be leading. Therefore, mastitis is, the major cause of economic loss in the dairy industry and, as a result of preventing the development is in strong demand.
Mastitis is, various bacterial species is caused by the complex disease, in their bacterial species, Staphylococcus aureus (Staphylococcus aureus, S. aureus) is the most common. Therefore, for the purpose of prevention of mastitis, bacterial vaccines and the target have been developed (Patent Document 1).
Has been already, (registered trademark, manufactured by HIPRA) STARTVAC, (registered trademark, manufactured by Boehringer Ingelheim) or the like Lysigin, vaccines and the target S. aureus, have been commercially available.
However, most of these muscle injection type vaccine, serum IgG antibody titer in an increased, contributing to the protection of non-bacterial infection (such as IgA) IgG antibody titer in the mammary gland does not increase, is not sufficiently able to induce cellular immune response.
In addition, S. aureus, an extremely early stage mammary epithelial cells to invade into the, as a result, the bacteria antibodies immunologically state becomes less vulnerable to attack.
Therefore, in the mammary gland from S. aureus such as IgA antibody titer immediately upon contact with the enhanced, the microbial infection can be effectively suppressed has been desired the development of vaccines.
Scope of claims (In Japanese)[請求項1]
 黄色ブドウ球菌由来の抗原と、疎水性の官能基及びカチオン性の官能基が側鎖として付加されている多糖からなるナノゲルとを含む、ウシ乳房炎を予防するための、粘膜ワクチン組成物。

[請求項2]
 前記疎水性の官能基がコレステリル基である、請求項1に記載の粘膜ワクチン組成物。

[請求項3]
 前記多糖がプルランである、請求項1又は2に記載の粘膜ワクチン組成物。

[請求項4]
 前記カチオン性の官能基がアミノ基である、請求項1~3のうちのいずれか一項に記載の粘膜ワクチン組成物。

[請求項5]
 黄色ブドウ球菌由来の抗原を経鼻投与するための、請求項1~4のうちのいずれか一項に記載の粘膜ワクチン組成物。

[請求項6]
 ウシ乳房炎を予防するための方法であって、
 ウシの粘膜に、請求項1~4のうちのいずれか一項に記載の粘膜ワクチン組成物を投与する工程を含む、方法。

[請求項7]
 ウシ乳房炎を予防するための方法であって、
 ウシの鼻腔内粘膜に、請求項1~5のうちのいずれか一項に記載の粘膜ワクチン組成物を投与する工程を含む、方法。

[請求項8]
 前記経鼻ワクチン組成物が投与される鼻腔内粘膜が、鼻腔内深部の咽頭扁桃である、請求項7に記載の方法。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION
  • KYOTO UNIVERSITY
  • TOHOKU UNIVERSITY
  • Inventor
  • HAYASHI Tomohito
  • KIKU Yoshio
  • NAGASAWA Yuya
  • AKIYOSHI Kazunari
  • SAWADA Shin-ichi
  • ASO Hisashi
  • NOCHI Tomonori
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by e-mail or facsimile if you have any interests on this patent. Thanks.

PAGE TOP

close
close
close
close
close
close